Ground Zero Pharma Opens New Office In Brisbane
Augments staff in regulatory, non-clinical and biologics chemistry, manufacturing and controls areas
Ground Zero Pharma (GZP) has opened a new office in downtown Brisbane, Australia in July, to better support an expanding Australian clientele in taking their programs to the FDA. The company is now adding Australia-based associates with FDA, TGA and EMEA experience to increase access to its expertise in regulatory-based medical product development and the local client's ability to meet conveniently with their staff.
GZP also augmented its staff in the regulatory, nonclinical, and biologics chemistry, manufacturing and controls areas to further serve its clients.
Through constant communication with the FDA in the form of pre-pre-IND, pre-IND, and mid-phase meetings with the FDA, the company received first-cycle clearance to proceed with clinical trials for INDs submitted in 2008 and 2009.
Ground Zero Pharmaceuticals is an Irvine, South-California-based biotechnology center, providing strategic and tactical consulting support in regulatory affairs and product development to pharmaceutical, biotechnology and medical device industries.
Related Insight
Suppliers Directory
Echo Pharmaceuticals - Advanced Technology Platform for Drug Delivery Systems, Formulation and Isolation
Echo Pharmaceuticals is a technology-based pharmaceutical drug development company, with a patented drug delivery technology, Alitra™, to formulate lipophilic active drug candidates into optimal delivery systems and innovative medicines suitable for clinical trials.
Drug Research > Drug Delivery > Suppliers
Genoma España - Applied Genomics and Biotechnology Innovation
Genoma España was created in 2002 to improve the worldwide competitiveness of Spanish research on applied genomics.
Suppliers
Gerteis - Roller Compactor Dry Granulators
Gerteis® is a Swiss manufacturer of advanced high quality roller compactor dry granulators who have set the standard with their unique dry granulation technology. Their understanding of the dry granulation process combined with patented roller compaction systems make Gerteis® the technology leaders in the field of dry granulation.
Suppliers
B&C Group - Packaging and Logistics Services
B&C Group is a Clinical Expert that provides world-class packaging and logistics services through Innovative technology and continuous improvement in Quality standards. By re-engineering logistics processes through our centres of excellence, we provide Flexible and Efficient solutions for the packaging, distribution, transport and storage or archiving of all clinical trial materials, Investigational Medicinal Products and biological specimens.
Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Intelligence
Contamination Problems? We Solve Them
Published by Phage Consultants
White Papers
Plastic Volumetric Flasks and Reagent Bottles Now Also With Light Protection
Published by VITLAB®
White Papers
Biocon Launches Haselmeier's Insulin Pen in India
Published by Haselmeier
White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.